Synergistic latency reversal by the IAP antagonist AZD5582 and BET inhibitor JQ1, combined with Nef ablation, facilitates immune-mediated elimination of latently HIV-1-infected T-cells
Dylan Postmus, Sui Ting Hui, Bengisu Akbil, Jenny Jansen, Dominic Wooding, Oya Cingöz, Christine Goffinet
This study shows that combining IAP antagonist AZD5582, BET inhibitor JQ1, and Nef ablation enhances immune-mediated elimination of HIV-1 latently infected T-cells.
bioRxiv · Aug 6, 2025 · PreprintMicrobiology